Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.
| Revenue (Most Recent Fiscal Year) | $43.26M |
| Net Income (Most Recent Fiscal Year) | $-45.31M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.33 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -257.17% |
| Net Margin (Trailing 12 Months) | -260.55% |
| Return on Equity (Trailing 12 Months) | -56.17% |
| Return on Assets (Trailing 12 Months) | -33.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.60 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | -- |
| Free Float | -- |
| Market Capitalization | -- |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 1.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.73% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |